Biosystems unit eyes Rs 200 cr reagents production in 5 yrs

Tags: News
Biosystems Diagnostics, a joint venture between Chennai-based Trivitron Healthcare and Spanish company BioSystems hopes to produce reagents worth Rs 200 crore in the next three to five years. The JV opened its manufacturing facility at Trivitron Medical Technology Park in Chennai on Monday.

BioSystems is one of the leading manufacturers of clinical chemistry reagents and instruments, immunofluorescence reagents and instruments as well as immunoturbidimetry reagents for over three decades.

The facility has a built-up area of 45,000 sq ft and has a capacity of one lakh litres of reagents per year. The JV has invested $10 million in the facility.

“This plant would be incorporating all contemporary technologies and comply with European Standards for its operations and would be at par with the global standards in every way. The plant design is scalable to double the capacity in future. This facility will produce reagent worth over Rs 200 crore during next three to five years and it would not only cater to the domestic market but also supply to the other overseas markets.”

The Indian market for diagnostic reagents is highly dependent on imports. Almost 80 per cent of the products are brought into the country from the developed world, mainly US and Europe. Apart from catering to the domestic market the company will also look at exporting the products to emerging markets in Asia, Africa, Latin America and West Asia.

“Our association with Trivitron will successfully help the two leading companies to leverage its respective strengths in marketing and manufacturing,” said Antonio Elduque, CEO, Biosystems.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • This is right time for retail investors to enter the debt market

    Quite often, retail investors are ridiculed for entering the equities market in droves, signalling the first signs of a bubble on the Street.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Arun Nigavekar

Cost of education must be controlled

In India, we pay very little attention to the cost ...

Zehra Naqvi

What imperfections in nature teach man

Each one of us has faced a time when we ...

Dharmendra Khandal

A wondrous world under the ground

Burrows and dens are safe homes for many kinds of ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture